Perceptronix Announces Completion of ClearVu Elite Clinical Study
Perceptronix Medical Inc. announced the completion of their clinical study entitled "Spectral Imaging of Early lung cancer and Pre-cancerous Lesions" using the Company´s ClearVu Elite(TM) system. Perceptronix is a laboratory service and medical device company focused on the development and commercialization of effective technologies that can improve the early detection, localization, diagnosis and follow-up of cancer. The Company´s initial focus is lung cancer.
The study, which was conducted using the Perceptronix ClearVu Elite(TM) system, aimed to develop a robust decision-making algorithm based on estimating physiological and morphological properties of lung tissue from the non-contact spectral measurement to detect early cancerous lesions. Historically, this process has been difficult to incorporate in imaging systems. Current clinical data suggests that by incorporating specific algorithms to the system the rate of false positive biopsies can be reduced by 50% with minimal or no loss of sensitivity compared with autofluorescence imaging alone.
"The positive results of this study are evidence that the estimated physiological properties of lung tissue can provide information which is useful in identifying early stage cancer. The results also provide valuable insight into a new endoscopic modality for imaging tissue physiology and functionality," comments Dr. Yasser Fawzy, lead scientist in the study and inventor of lung modelling diagnostic algorithms.
ClearVu Elite(TM) is an endoscopy accessory system composed of a camera with its own digital imaging system designed to add practical, real-time spectral analysis to autofluorescence imaging. ClearVu Elite(TM) is able to offer assessment of suspicious tissue before a biopsy is taken. An innovation in cancer imaging, ClearVu Elite(TM) is anticipated to have significant clinical impact in the detection and localization of early lung cancer.
Other news from the department research and development
